VERTEX PHARMACEUTICALS INC / MA (VRTX)
Vertex Pharmaceuticals is a biotechnology company that develops medicines for serious diseases and depends on China-based suppliers for portions of its supply chain.
| Ticker | VRTX |
|---|
| Company | VERTEX PHARMACEUTICALS INC / MA |
|---|
| Exchange | Nasdaq |
|---|
| Headquarters | BOSTON, MA |
|---|
Income statement — period ending 2026-06-30
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $1,123,500,000 |
|---|
| Cost of Goods and Services Sold | $489,200,000 |
|---|
| Earnings Per Share, Basic | 4 USD/shares |
|---|
| Earnings Per Share, Diluted | 4 USD/shares |
|---|
| Gross Profit (derived) | $2,844,700,000 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $1,391,800,000 |
|---|
| Income Tax Expense (Benefit) | $292,000,000 |
|---|
| Net Income (Loss) Attributable to Parent | $1,099,800,000 |
|---|
| Operating Income (Loss) | $1,246,900,000 |
|---|
| Other Nonoperating Income (Expense) | $24,300,000 |
|---|
| Revenue from Contract with Customer, Excluding Assessed Tax | $3,333,900,000 |
|---|
| Selling, General and Administrative Expense | $582,200,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $336,600,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 255,200,000 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 253,700,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro